Psoriasis – Pipeline Review, H2 2012
出 版 商：Global Markets Direct
出版日期：2012/08/31
頁 數：416頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Psoriasis – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Psoriasis - Pipeline Review, H2 2012', provides an overview of the Psoriasis therapeutic pipeline. This report provides information on the therapeutic development for Psoriasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psoriasis. 'Psoriasis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Psoriasis.
- A review of the Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Psoriasis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Psoriasis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Psoriasis pipeline depth and focus of Psoriasis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Summary
Global Markets Direct’s, 'Psoriasis - Pipeline Review, H2 2012', provides an overview of the Psoriasis therapeutic pipeline. This report provides information on the therapeutic development for Psoriasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psoriasis. 'Psoriasis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Psoriasis.
- A review of the Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Psoriasis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Psoriasis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Psoriasis pipeline depth and focus of Psoriasis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 7
Psoriasis Overview 8
Therapeutics Development 9
Psoriasis Therapeutics under Development by Companies 11
Psoriasis Therapeutics under Investigation by Universities/Institutes 20
Late Stage Products 22
Mid Clinical Stage Products 23
Early Clinical Stage Products 24
Discovery and Pre-Clinical Stage Products 25
Psoriasis Therapeutics – Products under Development by Companies 26
Psoriasis Therapeutics – Products under Investigation by Universities/Institutes 35
Companies Involved in Psoriasis Therapeutics Development 36
Psoriasis – Therapeutics Assessment 132
Drug Profiles 140
Psoriasis Therapeutics – Drug Profile Updates 326
Psoriasis Therapeutics – Discontinued Products 377
Psoriasis Therapeutics - Dormant Products 380
Psoriasis – Product Development Milestones 391
Appendix 399
List of Tables
Number of Products Under Development for Psoriasis, H2 2012 25
Products under Development for Psoriasis – Comparative Analysis, H2 2012 26
Number of Products under Development by Companies, H2 2012 28
Number of Products under Development by Companies, H2 2012 (Contd..1) 29
Number of Products under Development by Companies, H2 2012 (Contd..2) 30
Number of Products under Development by Companies, H2 2012 (Contd..3) 31
Number of Products under Development by Companies, H2 2012 (Contd..4) 32
Number of Products under Development by Companies, H2 2012 (Contd..5) 33
Number of Products under Development by Companies, H2 2012 (Contd..6) 34
Number of Products under Development by Companies, H2 2012 (Contd..7) 35
Number of Products under Investigation by Universities/Institutes, H2 2012 37
Comparative Analysis by Late Stage Development, H2 2012 38
Comparative Analysis by Mid Clinical Stage Development, H2 2012 39
Comparative Analysis by Early Clinical Stage Development, H2 2012 40
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 41
Products under Development by Companies, H2 2012 42
Products under Development by Companies, H2 2012 (Contd..1) 43
Products under Development by Companies, H2 2012 (Contd..2) 44
Products under Development by Companies, H2 2012 (Contd..3) 45
Products under Development by Companies, H2 2012 (Contd..4) 46
Products under Development by Companies, H2 2012 (Contd..5) 47
Products under Development by Companies, H2 2012 (Contd..6) 48
Products under Development by Companies, H2 2012 (Contd..7) 49
Products under Development by Companies, H2 2012 (Contd..8) 50
Products under Investigation by Universities/Institutes, H2 2012 51
Alcon, Inc., H2 2012 52
Genzyme Corporation, H2 2012 53
Johnson & Johnson, H2 2012 54
Kyowa Hakko Kirin Co., Ltd., H2 2012 55
Abbott Laboratories, H2 2012 56
Valeant Pharmaceuticals International, H2 2012 57
Amgen Inc., H2 2012 58
Eli Lilly and Company, H2 2012 59
GlaxoSmithKline plc, H2 2012 60
Biotest AG, H2 2012 61
Merck & Co., Inc., H2 2012 62
Stiefel Laboratories, Inc., H2 2012 63
AbGenomics International, Inc., H2 2012 64
Albany Molecular Research, Inc., H2 2012 65
XenoPort, Inc., H2 2012 66
BioLineRx, Ltd., H2 2012 67
ApoPharma, H2 2012 68
Celltrion, Inc., H2 2012 69
Actelion Ltd, H2 2012 70
Astellas Pharma Inc., H2 2012 71
Biocon Limited, H2 2012 72
Cephalon, Inc., H2 2012 73
Dr. Reddy's Laboratories Limited, H2 2012 74
Eisai Co., Ltd., H2 2012 75
LEO Pharma A/S, H2 2012 76
Pfizer Inc., H2 2012 77
Celgene Corporation, H2 2012 78
Incyte Corporation, H2 2012 79
4SC AG, H2 2012 80
Addex Pharmaceuticals, H2 2012 81
Can-Fite BioPharma Ltd., H2 2012 82
Idera Pharmaceuticals, Inc., H2 2012 83
Karo Bio, H2 2012 84
Almirall, S.A., H2 2012 85
Lupin Limited, H2 2012 86
Bionomics Limited, H2 2012 87
NexMed, Inc., H2 2012 88
NicOx SA, H2 2012 89
Nuvo Research Inc., H2 2012 90
KOLON LIFE SCIENCE INC., H2 2012 91
Protalix BioTherapeutics, Inc., H2 2012 92
ProMetic Life Sciences Inc., H2 2012 93
Phytopharm Plc, H2 2012 94
Genizon BioSciences, Inc., H2 2012 95
Cytos Biotechnology AG, H2 2012 96
Biotie Therapies Corp., H2 2012 97
Provectus Pharmaceuticals, Inc., H2 2012 98
Sareum Holdings plc, H2 2012 99
Proximagen Neuroscience plc., H2 2012 100
Hybrigenics S.A., H2 2012 101
R-Tech Ueno, Ltd., H2 2012 102
Paloma Pharmaceuticals, Inc., H2 2012 103
Morphotek, Inc., H2 2012 104
D-Pharm Ltd., H2 2012 105
Affimed Therapeutics AG, H2 2012 106
Viron Therapeutics, Inc., H2 2012 107
Deltanoid Pharmaceuticals Inc., H2 2012 108
Jenrin Discovery, Inc., H2 2012 109
Acceleron Pharma, Inc., H2 2012 110
Phenex Pharmaceuticals AG, H2 2012 111
MIKA Pharma GmbH, H2 2012 112
Cosmix Molecular Biologicals GmbH, H2 2012 113
CREABILIS Therapeutics S.r.l., H2 2012 114
BioNumerik Pharmaceuticals, Inc., H2 2012 115
Anacor Pharmaceuticals, Inc., H2 2012 116
JADO Technologies GmbH., H2 2012 117
Circassia Holdings Ltd., H2 2012 118
Therapeutics Incorporated, H2 2012 119
Funxional Therapeutics Ltd, H2 2012 120
Gene Signal International SA., H2 2012 121
Catabasis Pharmaceuticals, Inc., H2 2012 122
Syntrix Biosystems, Inc., H2 2012 123
S*BIO Pte Ltd, H2 2012 124
Vascular Biogenics Ltd., H2 2012 125
SARcode Corporation, H2 2012 126
Inimex Pharmaceuticals, Inc., H2 2012 127
Sosei Co. Ltd., H2 2012 128
Welichem Biotech Inc., H2 2012 129
Redox Pharmaceutical Corporation, H2 2012 130
CBio Limited, H2 2012 131
SWITCH Biotech LLC, H2 2012 132
Laboratorios SALVAT S.A., H2 2012 133
Avesthagen Limited, H2 2012 134
Maruho Co.,Ltd., H2 2012 135
Pharis Biotec GmbH, H2 2012 136
Centocor Ortho Biotech, Inc., H2 2012 137
Aphoenix, Inc., H2 2012 138
Cellceutix Pharmaceuticals, Inc., H2 2012 139
Amplimmune, Inc., H2 2012 140
Lycera Corp., H2 2012 141
CalciMedica, Inc., H2 2012 142
Femta Pharmaceuticals, Inc., H2 2012 143
Celtic Pharmaceutical Holdings L.P., H2 2012 144
XBiotech USA, Inc., H2 2012 145
Clarassance, Inc., H2 2012 146
Advancell, H2 2012 147
Assessment by Monotherapy Products, H2 2012 148
Assessment by Combination Products, H2 2012 149
Assessment by Stage and Route of Administration, H2 2012 152
Assessment by Stage and Molecule Type, H2 2012 155
Psoriasis Therapeutics – Drug Profile Updates 342
Psoriasis Therapeutics – Discontinued Products 393
Psoriasis Therapeutics – Discontinued Products (Contd..1) 394
Psoriasis Therapeutics – Discontinued Products (Contd..2) 395
Psoriasis Therapeutics – Dormant Products 396
Psoriasis Therapeutics – Dormant Products (Contd..1) 397
Psoriasis Therapeutics – Dormant Products (Contd..2) 398
Psoriasis Therapeutics – Dormant Products (Contd..3) 399
Psoriasis Therapeutics – Dormant Products (Contd..4) 400
Psoriasis Therapeutics – Dormant Products (Contd..5) 401
Psoriasis Therapeutics – Dormant Products (Contd..6) 402
Psoriasis Therapeutics – Dormant Products (Contd..7) 403
Psoriasis Therapeutics – Dormant Products (Contd..8) 404
Psoriasis Therapeutics – Dormant Products (Contd..9) 405
Psoriasis Therapeutics – Dormant Products (Contd..10) 406
List of Figures
Number of Products under Development for Psoriasis, H2 2012 25
Products under Development for Psoriasis – Comparative Analysis, H2 2012 26
Products under Development by Companies, H2 2012 27
Products under Investigation by Universities/Institutes, H2 2012 36
Late Stage Products, H2 2012 38
Mid Clinical Stage Products, H2 2012 39
Early Clinical Stage Products, H2 2012 40
Discovery and Pre-Clinical Stage Products, H2 2012 41
Assessment by Monotherapy Products, H2 2012 148
Assessment by Combination Products, H2 2012 149
Assessment by Route of Administration, H2 2012 150
Assessment by Stage and Route of Administration, H2 2012 151
Assessment by Molecule Type, H2 2012 153
Assessment by Stage and Molecule Type, H2 2012 154
Table of Contents 2
Introduction 7
Psoriasis Overview 8
Therapeutics Development 9
Psoriasis Therapeutics under Development by Companies 11
Psoriasis Therapeutics under Investigation by Universities/Institutes 20
Late Stage Products 22
Mid Clinical Stage Products 23
Early Clinical Stage Products 24
Discovery and Pre-Clinical Stage Products 25
Psoriasis Therapeutics – Products under Development by Companies 26
Psoriasis Therapeutics – Products under Investigation by Universities/Institutes 35
Companies Involved in Psoriasis Therapeutics Development 36
Psoriasis – Therapeutics Assessment 132
Drug Profiles 140
Psoriasis Therapeutics – Drug Profile Updates 326
Psoriasis Therapeutics – Discontinued Products 377
Psoriasis Therapeutics - Dormant Products 380
Psoriasis – Product Development Milestones 391
Appendix 399
List of Tables
Number of Products Under Development for Psoriasis, H2 2012 25
Products under Development for Psoriasis – Comparative Analysis, H2 2012 26
Number of Products under Development by Companies, H2 2012 28
Number of Products under Development by Companies, H2 2012 (Contd..1) 29
Number of Products under Development by Companies, H2 2012 (Contd..2) 30
Number of Products under Development by Companies, H2 2012 (Contd..3) 31
Number of Products under Development by Companies, H2 2012 (Contd..4) 32
Number of Products under Development by Companies, H2 2012 (Contd..5) 33
Number of Products under Development by Companies, H2 2012 (Contd..6) 34
Number of Products under Development by Companies, H2 2012 (Contd..7) 35
Number of Products under Investigation by Universities/Institutes, H2 2012 37
Comparative Analysis by Late Stage Development, H2 2012 38
Comparative Analysis by Mid Clinical Stage Development, H2 2012 39
Comparative Analysis by Early Clinical Stage Development, H2 2012 40
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 41
Products under Development by Companies, H2 2012 42
Products under Development by Companies, H2 2012 (Contd..1) 43
Products under Development by Companies, H2 2012 (Contd..2) 44
Products under Development by Companies, H2 2012 (Contd..3) 45
Products under Development by Companies, H2 2012 (Contd..4) 46
Products under Development by Companies, H2 2012 (Contd..5) 47
Products under Development by Companies, H2 2012 (Contd..6) 48
Products under Development by Companies, H2 2012 (Contd..7) 49
Products under Development by Companies, H2 2012 (Contd..8) 50
Products under Investigation by Universities/Institutes, H2 2012 51
Alcon, Inc., H2 2012 52
Genzyme Corporation, H2 2012 53
Johnson & Johnson, H2 2012 54
Kyowa Hakko Kirin Co., Ltd., H2 2012 55
Abbott Laboratories, H2 2012 56
Valeant Pharmaceuticals International, H2 2012 57
Amgen Inc., H2 2012 58
Eli Lilly and Company, H2 2012 59
GlaxoSmithKline plc, H2 2012 60
Biotest AG, H2 2012 61
Merck & Co., Inc., H2 2012 62
Stiefel Laboratories, Inc., H2 2012 63
AbGenomics International, Inc., H2 2012 64
Albany Molecular Research, Inc., H2 2012 65
XenoPort, Inc., H2 2012 66
BioLineRx, Ltd., H2 2012 67
ApoPharma, H2 2012 68
Celltrion, Inc., H2 2012 69
Actelion Ltd, H2 2012 70
Astellas Pharma Inc., H2 2012 71
Biocon Limited, H2 2012 72
Cephalon, Inc., H2 2012 73
Dr. Reddy's Laboratories Limited, H2 2012 74
Eisai Co., Ltd., H2 2012 75
LEO Pharma A/S, H2 2012 76
Pfizer Inc., H2 2012 77
Celgene Corporation, H2 2012 78
Incyte Corporation, H2 2012 79
4SC AG, H2 2012 80
Addex Pharmaceuticals, H2 2012 81
Can-Fite BioPharma Ltd., H2 2012 82
Idera Pharmaceuticals, Inc., H2 2012 83
Karo Bio, H2 2012 84
Almirall, S.A., H2 2012 85
Lupin Limited, H2 2012 86
Bionomics Limited, H2 2012 87
NexMed, Inc., H2 2012 88
NicOx SA, H2 2012 89
Nuvo Research Inc., H2 2012 90
KOLON LIFE SCIENCE INC., H2 2012 91
Protalix BioTherapeutics, Inc., H2 2012 92
ProMetic Life Sciences Inc., H2 2012 93
Phytopharm Plc, H2 2012 94
Genizon BioSciences, Inc., H2 2012 95
Cytos Biotechnology AG, H2 2012 96
Biotie Therapies Corp., H2 2012 97
Provectus Pharmaceuticals, Inc., H2 2012 98
Sareum Holdings plc, H2 2012 99
Proximagen Neuroscience plc., H2 2012 100
Hybrigenics S.A., H2 2012 101
R-Tech Ueno, Ltd., H2 2012 102
Paloma Pharmaceuticals, Inc., H2 2012 103
Morphotek, Inc., H2 2012 104
D-Pharm Ltd., H2 2012 105
Affimed Therapeutics AG, H2 2012 106
Viron Therapeutics, Inc., H2 2012 107
Deltanoid Pharmaceuticals Inc., H2 2012 108
Jenrin Discovery, Inc., H2 2012 109
Acceleron Pharma, Inc., H2 2012 110
Phenex Pharmaceuticals AG, H2 2012 111
MIKA Pharma GmbH, H2 2012 112
Cosmix Molecular Biologicals GmbH, H2 2012 113
CREABILIS Therapeutics S.r.l., H2 2012 114
BioNumerik Pharmaceuticals, Inc., H2 2012 115
Anacor Pharmaceuticals, Inc., H2 2012 116
JADO Technologies GmbH., H2 2012 117
Circassia Holdings Ltd., H2 2012 118
Therapeutics Incorporated, H2 2012 119
Funxional Therapeutics Ltd, H2 2012 120
Gene Signal International SA., H2 2012 121
Catabasis Pharmaceuticals, Inc., H2 2012 122
Syntrix Biosystems, Inc., H2 2012 123
S*BIO Pte Ltd, H2 2012 124
Vascular Biogenics Ltd., H2 2012 125
SARcode Corporation, H2 2012 126
Inimex Pharmaceuticals, Inc., H2 2012 127
Sosei Co. Ltd., H2 2012 128
Welichem Biotech Inc., H2 2012 129
Redox Pharmaceutical Corporation, H2 2012 130
CBio Limited, H2 2012 131
SWITCH Biotech LLC, H2 2012 132
Laboratorios SALVAT S.A., H2 2012 133
Avesthagen Limited, H2 2012 134
Maruho Co.,Ltd., H2 2012 135
Pharis Biotec GmbH, H2 2012 136
Centocor Ortho Biotech, Inc., H2 2012 137
Aphoenix, Inc., H2 2012 138
Cellceutix Pharmaceuticals, Inc., H2 2012 139
Amplimmune, Inc., H2 2012 140
Lycera Corp., H2 2012 141
CalciMedica, Inc., H2 2012 142
Femta Pharmaceuticals, Inc., H2 2012 143
Celtic Pharmaceutical Holdings L.P., H2 2012 144
XBiotech USA, Inc., H2 2012 145
Clarassance, Inc., H2 2012 146
Advancell, H2 2012 147
Assessment by Monotherapy Products, H2 2012 148
Assessment by Combination Products, H2 2012 149
Assessment by Stage and Route of Administration, H2 2012 152
Assessment by Stage and Molecule Type, H2 2012 155
Psoriasis Therapeutics – Drug Profile Updates 342
Psoriasis Therapeutics – Discontinued Products 393
Psoriasis Therapeutics – Discontinued Products (Contd..1) 394
Psoriasis Therapeutics – Discontinued Products (Contd..2) 395
Psoriasis Therapeutics – Dormant Products 396
Psoriasis Therapeutics – Dormant Products (Contd..1) 397
Psoriasis Therapeutics – Dormant Products (Contd..2) 398
Psoriasis Therapeutics – Dormant Products (Contd..3) 399
Psoriasis Therapeutics – Dormant Products (Contd..4) 400
Psoriasis Therapeutics – Dormant Products (Contd..5) 401
Psoriasis Therapeutics – Dormant Products (Contd..6) 402
Psoriasis Therapeutics – Dormant Products (Contd..7) 403
Psoriasis Therapeutics – Dormant Products (Contd..8) 404
Psoriasis Therapeutics – Dormant Products (Contd..9) 405
Psoriasis Therapeutics – Dormant Products (Contd..10) 406
List of Figures
Number of Products under Development for Psoriasis, H2 2012 25
Products under Development for Psoriasis – Comparative Analysis, H2 2012 26
Products under Development by Companies, H2 2012 27
Products under Investigation by Universities/Institutes, H2 2012 36
Late Stage Products, H2 2012 38
Mid Clinical Stage Products, H2 2012 39
Early Clinical Stage Products, H2 2012 40
Discovery and Pre-Clinical Stage Products, H2 2012 41
Assessment by Monotherapy Products, H2 2012 148
Assessment by Combination Products, H2 2012 149
Assessment by Route of Administration, H2 2012 150
Assessment by Stage and Route of Administration, H2 2012 151
Assessment by Molecule Type, H2 2012 153
Assessment by Stage and Molecule Type, H2 2012 154
